Novartis AG Cash And Cash Equivalents
Novartis AG (NVS) had Cash And Cash Equivalents of $11.44 billion as of 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Notes
ifrs-full:CashAndCashEquivalents · last filed 2026-02-04
- 2025-12-31: Cash And Cash Equivalents $11.44B.
- 2025-06-30: Cash And Cash Equivalents $6.66B.
- 2025-03-31: Cash And Cash Equivalents $7.07B.
- 2024-12-31: Cash And Cash Equivalents $11.46B.
| Period end | Cash And Cash Equivalents |
|---|---|
| 2025-12-31 | $11.44B 20-F · filed 2026-02-04 |
| 2025-06-30 | $6.66B 6-K · filed 2025-07-17 |
| 2025-03-31 | $7.07B 6-K · filed 2025-07-17 |
| 2024-12-31 | $11.46B 20-F · filed 2026-02-04 |
| 2024-06-30 | $7.90B 6-K · filed 2025-07-17 |
| 2024-03-31 | $9.47B 6-K · filed 2025-07-17 |
| 2023-12-31 | $13.39B 20-F · filed 2026-02-04 |
| 2023-06-30 | $10.88B 6-K · filed 2024-07-18 |
| 2023-03-31 | $12.00B 6-K · filed 2024-07-18 |
| 2022-12-31 | $7.52B 20-F · filed 2026-02-04 |
| 2022-06-30 | $3.63B 6-K · filed 2023-07-18 |
| 2022-03-31 | $13.85B 6-K · filed 2023-07-18 |
| 2021-12-31 | $12.41B 20-F · filed 2025-01-31 |
| 2021-06-30 | $5.12B 6-K · filed 2022-07-19 |
| 2021-03-31 | $3.80B 6-K · filed 2022-07-19 |
| 2020-12-31 | $9.66B 20-F · filed 2024-01-31 |
| 2020-06-30 | $5.92B 6-K · filed 2021-07-21 |
| 2020-03-31 | $4.53B 6-K · filed 2021-07-21 |
| 2019-12-31 | $11.11B 20-F/A · filed 2023-05-15 |
| 2019-06-30 | $9.99B 6-K · filed 2020-07-21 |
| 2019-03-31 | $6.81B 6-K · filed 2020-07-21 |
| 2018-12-31 | $13.27B 20-F · filed 2022-02-02 |
| 2018-06-30 | $12.45B 6-K · filed 2019-07-18 |
| 2018-03-31 | $5.81B 6-K · filed 2019-07-18 |
| 2017-12-31 | $8.86B 20-F · filed 2021-01-26 |
| 2017-06-30 | $7.86B 6-K · filed 2018-07-18 |
| 2017-03-31 | $7.57B 6-K · filed 2018-07-18 |
| 2016-12-31 | $7.01B 20-F · filed 2020-01-29 |
| 2015-12-31 | $4.67B 20-F · filed 2019-01-30 |
| 2014-12-31 | $13.02B 6-K · filed 2018-01-24 |